Today at the 5th Annual Canada Science Policy Conference #CSPC2013. Genome Canada is sponsoring a Genomics, Public Policy and Society (GPS) series. Presenting a research brief today is Christopher McCabe, Professor at the University of Alberta and Don Husereau, Senior Associate at the Institute of Health Economics looking at the issue of science to value.
The Policy Brief itself explores needed steps in research, development and regulation to help with integrating new, personalized medicines and their associated technologies - including devices - into the Canadian health system. This is a key challenge for policy makers in Canada and around the world, and I've blogged about this before here on LillyPadCA.
As the Policy Brief is not yet complete and this session is intended to provide expert and room feedback in order to challenge and improve the findings, I can't provide a link of technical details for you yet, but will be sure to link to the final paper when it is posted on the Genome Canada website in the coming months. However, if you are interested in other GPS Policy Briefs, I encourage you to check out the Genome Canada website.
So, what are a number of the factors that impact the move from science to value? Well, at a very high level, a number of key factors are the technologies themselves, disease and its variations, and populations - the people who are of different backgrounds, ages and geographies in Canada.
The authors note that getting these pieces right, means that coordination across science, industry and payer communities will be imperative. That's right - collaboration that is inclusive and includes all the key players. The paper outlines three specific recommendations that, at a general level push policy makers to 1. Clearly define what constitutes value; 2. Explore options to improve and align to make the regulation and approval of these technologies more efficient and evidenced based; and 3. Getting the research policy 'machine' right between the discovery and applied research activities.
This kind of discussion and exploration of the personalized health dynamic in Canada and its potential for Canadians is key. From my perspective, ensuring that Canadians are part of this policy discussion, and that access is part of that value equation, will be important. I'm looking forward to reading the final paper when it is released.
Stay tuned, as I will be blogging again shortly as the day progresses at the Canadian Science Policy Conference.